Inventor · disambiguated record
Laura A. Vitale
Also filed as: VITALE LAURA · VITALE LAURA A
15 granted patents·11 pending applications·197 citations·filing 2004–2024
92Inventor score
Top patents by PatentIndex Score
26 records- 0196US9169325B2Antibodies that bind human CD27 and uses thereofKELER TIBOR·Filed 2011·Granted Oct 27, 2015·64 cites·19 claims
- 0296US7456264B2Human monoclonal antibodies against Bacillus anthracis protective antigenMEDAREX INC·Filed 2004·Granted Nov 25, 2008·88 cites·32 claims
- 0394US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 0491US8236318B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2008·Granted Aug 7, 2012·17 cites·19 claims
- 0590US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 0690US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 0786US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0885US11180566B2Antibodies that bind human CD27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2015·Granted Nov 23, 2021·4 cites·7 claims
- 0985US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1082US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 1181US8362214B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2009·Granted Jan 29, 2013·3 cites·11 claims
- 1279US8586720B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2012·Granted Nov 19, 2013·3 cites·6 claims
- 1378US8318165B2Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)KELER TIBOR·Filed 2007·Granted Nov 27, 2012·2 cites·25 claims
- 1476US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1575US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1672US8404820B2Human monoclonal antibodies against Bacillus anthracis protective antigenKELER TIBOR·Filed 2008·Granted Mar 26, 2013·0 cites·39 claims
- 1771US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 1871US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1970US2022227877A1Antibodies that bind human cd27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2064US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 2161US2024409639A1Anti-ilt4 and anti-pd-1 bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2260US9624300B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2012·Granted Apr 18, 2017·0 cites·5 claims
- 2359US2024417459A1Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereofCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2448US2018044429A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2548US2022177593A1Anti-axl antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2641US2012213771A1Antibodies that bind human cd27 and uses thereofKELER TIBOR·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Laura A. Vitale files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →